News archive
Showing 791 results
June 2012
-
Media Release
NPC Statement on Comments Made in Media Coverage of Paycheck Fairness Act
Novartis Pharmaceuticals Corporation (NPC) is aware of the recent Democratic Steering and Policy Committee session in the U.S. House of Representatives to discuss the Paycheck Fairness Act and… -
Media Release
NPC Statement on Comments Made in Media Coverage of Paycheck Fairness Act
May 2012
-
Media Release
Two new analyses reinforce consistent efficacy of Novartis therapy Gilenya across wide range of relapsing MS patients
• Data from FREEDOMS study show Gilenya reduced relapses in patients who discontinued another MS therapy due to side effects or inadequate efficacy• Analyses of five clinical studies show Gilenya,… -
Media Release
Two new analyses reinforce consistent efficacy of Novartis therapy Gilenya across wide range of relapsing MS patients
-
Media Release
TV host Phil Keoghan and professional women cyclists join Novartis to raise awareness of multiple sclerosis
- "Together in MS" partners professional cycling team members with people living with MS for Bike MS rides on tandem bicycles across the country- Phil Keoghan, MS advocate and TV host, rides tandem… -
Media Release
TV host Phil Keoghan and professional women cyclists join Novartis to raise awareness of multiple sclerosis
April 2012
-
Media Release
Higher dose of Novartis drug Exelon® Patch showed statistically significantly less decline in function in Alzheimer’s vs. lower dose
• In the trial, patients on Exelon Patch 13.3 mg/24 h showed less functional decline vs. 9.5 mg/24 h patch in mild to moderate Alzheimer’s disease• Numerical trend toward cognitive efficacy was seen… -
Media Release
Higher dose of Novartis drug Exelon® Patch showed statistically significantly less decline in function in Alzheimer’s vs. lower dose
-
Media Release
New extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MS
Results from open label phase III extension and 7-year phase II extension studies show sustained low disease activity on clinical and MRI measures in patients continuing on Gilenya (fingolimod)… -
Media Release
New extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MS
-
Media Release
Novartis announces update to United States prescribing information for MS therapy Gilenya following FDA review
Prescribing information (PI) includes new patient selection parameters based on certain cardiovascular considerations to aid in identifying patients for GilenyaUpdated Gilenya prescribing information… -
Media Release
Novartis announces update to United States prescribing information for MS therapy Gilenya following FDA review